Insight

Jun Gong: ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer

Jun Gong/LinkedIn

Nov 19, 2024, 20:48

Jun Gong: ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer

Jun Gong, Medical Oncologist and Researcher at Cedars-Sinai Medical Center, shared a post on X about a recent paper by him and colleagues published in Taylor and Francis Research Insights’ Immunotherapy Journal.

“Just published! ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer following failure to clear MRD with adjuvant oxalipatin-based chemo.

Full access here.”

“ctDNA-guided adjuvant immunotherapy in colorectal cancer”

Authors: Nicholas Burley, Yurhee Lee, Louisa Liu, Alexandra Gangi, Yosef Nasseri, Katelyn Atkins, Karen Zaghiyan, Zuri Murrell, Arsen Osipov, Andrew Hendifar, Megan Hitchins, Jun Gong.

Jun Gong: ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer

More posts featuring Jun Gong.

Alexandra Gangi Andrew Hendifar Arsen Osipov cancer Colon cancer immunotherapy Jun Gong Karen Zaghiyan Katelyn Atkins Louisa Liu Megan Hitchins Nicholas Burley OncoDaily Oncology Yosef Nasseri Yurhee Lee Zuri Murrell

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer